Can you drink alcohol on tirzepatide or semaglutide?
None of the US or EU labels for tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy) bans alcohol. The NHS advises avoiding it, as it can worsen nausea and vomiting. If you also take insulin or a sulfonylurea, drinking raises the risk of low blood sugar, which Diabetes UK says can last up to 24 hours.
What do the labels say about alcohol?
We found no warning about drinking alcohol in any of the US or EU labels for Mounjaro, Zepbound, Ozempic or Wegovy.1,2,3,4,5,6,7
Tirzepatide labels mention alcohol only as benzyl alcohol, an ingredient in some pens and vials.1,5 Semaglutide labels mention it mainly as the swab used to clean the skin.3,4 Health services go further. The NHS pages for tirzepatide and semaglutide say it’s best not to drink, because alcohol can increase feeling or being sick.8,9 India’s ESI 2025 obesity guideline lists “avoid alcohol” among its tips for easing side effects of these medicines.10 The NHS weight loss plan adds that alcohol has 7 calories a gram, almost as many as fat.23
Why can drinking make the side effects worse?
Feeling sick (nausea) affects at least 1 in 10 people on these medicines, and the NHS says alcohol can make it worse.5,6,8
In the US Mounjaro label’s diabetes trials, 12% to 18% had nausea, against 4% on a dummy injection (placebo).1 In the US Ozempic label’s trials it was 16% to 20%, against 6%.3 Rates were higher in the weight-loss trials: 25% to 29% against 8% in the US Zepbound label, and 44% on Wegovy 2.4 mg against 16% in the US Wegovy label.2,4
Vomiting and diarrhoea can dry you out (dehydration). The US labels report kidney injury, mostly in people dehydrated this way.1,3 Diabetes UK suggests a glass of water between drinks to avoid alcohol’s “dehydrating effects”.11 Both US labels also warn about a swollen pancreas (pancreatitis).1,3 The NHS names drinking a lot of alcohol as one of its 2 most common causes.12
Is drinking riskier if you take them for diabetes?
Yes, if you also take insulin or a sulfonylurea such as glimepiride, because each of these can cause low blood sugar (a hypo).1,3,13
The US and EU labels say that taking tirzepatide or semaglutide with insulin or a sulfonylurea raises the risk of hypos. The US labels add that some can be severe.1,3,5,6 The US glimepiride label says hypos are more likely “when alcohol is ingested”.13 Diabetes UK says this risk can last up to 24 hours after drinking.11
Hypo signs listed in the US Ozempic leaflet include slurred speech, confusion, drowsiness and shakiness.3 Diabetes UK warns that people sometimes mistake a hypo for being drunk.11
Can these medicines make you drink less?
In 3 small trials of people with alcohol use disorder, semaglutide cut some drinking measures, and we found no published tirzepatide results yet.14,15,16,17
A 9-week US trial of low-dose semaglutide in 48 adults cut drinks per drinking day and craving, but not the number of drinking days.14 A Danish trial gave 108 adults with obesity talk therapy plus semaglutide 2.4 mg weekly or placebo for 26 weeks. Heavy-drinking days fell 41 percentage points, against 26 on placebo. Stomach side effects were more common on semaglutide, mostly mild to moderate.15 An 8-week trial of semaglutide tablets in 50 adults missed its main measure, craving, but cut heavy-drinking days.16
On ClinicalTrials.gov, 7 tirzepatide studies involving alcohol had posted no results by 16 Nov 2026.17 Neither the US Mounjaro nor the US Ozempic label lists alcohol use disorder among its uses.1,3
What do people on GLP‑1 medicines report about alcohol?
From public patient forums: 606 Reddit threads in r/Zepbound, r/Mounjaro, r/mounjarouk, r/Semaglutide, r/WegovyWeightLoss and r/Ozempic, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the trials, in part Many say their wish to drink dropped. Many others notice no change at all. In 3 small trials of people with alcohol use disorder, semaglutide cut some drinking measures but not others.14,15,16
- Matches the NHS Many describe nausea, vomiting, reflux or diarrhoea after only 1 or 2 drinks. The NHS says alcohol can increase feeling or being sick on these medicines.8,9
- Matches a small study Several say a drink’s effect arrives late, sometimes all at once. A 20-person pilot study found breath alcohol and felt effects rose more slowly on GLP‑1 medicines. Many others report the opposite: drinks hitting faster or harder.18
Advice people share
- Matches Diabetes UK Several suggest water between drinks to stay hydrated. Diabetes UK gives the same tip to avoid alcohol’s drying effect.11
- Matches the ESI guideline Several avoid beer, cider and other fizzy drinks because they bloat. India’s ESI 2025 guideline lists avoiding fizzy drinks among its tips for side effects.10
- Label says otherwise Several describe skipping or delaying a dose so they can drink at an event. The US Mounjaro and Ozempic labels cover only a missed dose, then say to resume the regular weekly schedule. Neither gives alcohol as a reason to pause.1,3
In your country
The NHS advice and the low blood sugar risk with insulin or a sulfonylurea apply everywhere. Australia’s consumer leaflets add an alcohol line, and we had no label to open for three countries.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian consumer leaflets for Ozempic and Mounjaro KwikPen say to tell your doctor if you drink, as alcohol may hide the signs of low blood sugar or make it worse.19,20 The Wegovy FlexTouch leaflet does not mention alcohol.21
Emergency number: 000
Life on a GLP-1 in Australia: food, exercise, injections, heat
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The answer above applies.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The answer above applies.
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 112
Leben mit der Abnehmspritze: Essen, Sport, Spritzen, Lagerung
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We had no Indian label to open, so this page relies on the US and EU labels cited above. India’s ESI 2025 guideline advises avoiding alcohol.10
Emergency number: 112
Life on a GLP-1: food, exercise, injections, fasting (India)
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We had no Saudi label to open, so this page relies on the US and EU labels cited above.
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We had no UAE label to open, so this page relies on the US and EU labels cited above.
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 999
Life on a GLP-1 in the UK: food, exercise, injections, fasting
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Life on a GLP-1 in the US: food, exercise, injections, travel
Contact your prescriber or a doctor right away if you have severe stomach pain that won’t go away, with or without vomiting, sometimes felt through to your back, or nausea, vomiting or diarrhoea that won’t go away.3
Read the full picture
Related questions
Sources
- Eli Lilly. Mounjaro (tirzepatide): US prescribing information, revised 08/2026, sections 1, 2.1, 5.2, 5.3, 5.5, 6.1 and 11. PDF
- Eli Lilly. Zepbound (tirzepatide): US prescribing information, revised 08/2026, sections 6.1 and 11. PDF
- Novo Nordisk. Ozempic (semaglutide): US prescribing information, Medication Guide and instructions for use, revised 05/2026, sections 1, 2.1, 5.2, 5.5, 5.6 and 6.1. PDF
- Novo Nordisk. Wegovy (semaglutide): US prescribing information and instructions for use, revised 06/2026, section 6.1. PDF
- European Medicines Agency. Mounjaro: EU product information, sections 4.4 and 4.8. PDF
- European Medicines Agency. Ozempic: EU product information, sections 4.4 and 4.8. PDF
- European Medicines Agency. Wegovy: EU product information. PDF
- NHS (UK). Tirzepatide, “Food, drink and alcohol with tirzepatide”. nhs.uk
- NHS (UK). Semaglutide, “Food, drink and alcohol with semaglutide”. nhs.uk
- Madhu SV, Kapoor N, Das S, Raizada N, Kalra S. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025). Indian J Endocrinol Metab 2025;29:355–365. Table 6. DOI · PMID 40917319
- Diabetes UK. Alcohol and diabetes. Last reviewed 17 December 2024. diabetes.org.uk
- NHS (UK). Acute pancreatitis. nhs.uk
- Glimepiride tablets: US prescribing information (DailyMed), section 5.1. dailymed.nlm.nih.gov
- Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. Abstract read. DOI · PMID 39937469
- Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet 2026;407:1687–1698. Abstract read. DOI · PMID 42070571
- Schacht JP, Sakai JT, Raymond K, Shelton R. Oral semaglutide for alcohol use disorder: a randomized clinical trial. Am J Psychiatry 2026;183(9):636–645. Abstract read. DOI · PMID 42522065
- ClinicalTrials.gov. Search: condition “alcohol”, intervention “tirzepatide” (7 studies, none with posted results, checked 16 Nov 2026), including Tirzepatide for Alcohol Use Disorder (NCT06994338) and Impact of GLP‑1 Receptor Agonist Therapy on Alcohol Pharmacokinetics (NCT07758231).
- Quddos F et al. A preliminary study of the physiological and perceptual effects of GLP‑1 receptor agonists during alcohol consumption in people with obesity. Sci Rep 2025;15:32385. Abstract read. DOI · PMID 41093891
- Novo Nordisk. Ozempic: Australian Consumer Medicine Information, “Drinking alcohol”. PDF
- Eli Lilly. Mounjaro KwikPen: Australian Consumer Medicine Information, “Drinking alcohol”. medsinfo.com.au
- Novo Nordisk. Wegovy FlexTouch: Australian Consumer Medicine Information. PDF
- NHS (UK). Low blood sugar (hypoglycaemia). nhs.uk
- NHS (UK). NHS weight loss plan, week 5, “Calories in alcohol”. PDF
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write